PACS Group (NYSE: PACS) experienced a significant share price decline following the resignation of its Chief Financial Officer amidst a probe into alleged financial misconduct and revelations of revenue overstatements. The healthcare provider also faces a potential NYSE delisting.

PACS Group (NYSE: PACS) shares declined significantly on Tuesday, September 9, 2025, with the stock falling 29.3% to $8.0025, reaching a 52-week low of $7.50. This movement occurred amidst heavy trading volume and followed an announcement concerning the company's Chief Financial Officer and revelations of financial irregularities. The stock had previously plummeted 38% in after-hours trading on September 2, 2025, immediately after the initial news broke.

CFO Resignation and Financial Misconduct Probe

The sharp downturn in PACS Group's stock is primarily attributed to the resignation of Chief Financial Officer Derick Apt. His departure came amidst an ongoing internal probe into alleged financial misconduct, specifically concerning the acceptance of "high-value items" from individuals associated with the company's business partners, a violation of company policy. Following Apt's resignation, Mark Hancock, who previously served as CFO from January 2013 to January 2024, has been appointed as interim Chief Financial Officer.

Further compounding investor concerns are the company's announced financial restatements. PACS Group has preliminarily estimated that it overstated revenue by approximately $15-17 million for the first quarter of 2024 and $46-48 million for the second quarter of 2024. These errors are primarily linked to revenue recognition issues related to Medicare Part B billings for respiratory and certain therapy services. This marks a concerning pattern, as the company faced similar allegations in November 2024 from Hindenburg Research, which claimed PACS Group inflated numbers by abusing COVID-era waivers, leading to a 28-27.8% stock drop at that time.

NYSE Delisting Threat and Market Reaction

Adding to the uncertainty, PACS Group is currently facing a New York Stock Exchange (NYSE) delisting threat due to missed financial filings. The company has been granted an extension until November 19, 2025, to become current with its SEC obligations and regain compliance with NYSE listing standards. The company has also entered a forbearance agreement and amended its credit agreement, further contributing to market apprehension regarding its financial stability and governance practices.

The market's reaction reflects deep investor concern over governance failures and financial transparency issues. The stock's daily trading volume surged to 5.83 million shares, significantly higher than its average volume of 1.63 million, underscoring the extreme volatility and liquidity crisis facing the company. Over the past year, PACS Group's stock has seen a substantial downturn, plummeting 76.81%, and its market capitalization has decreased by 76.10% to $1.51 billion as of September 12, 2025, from $3.15 billion at its IPO on April 11, 2024.

Broader Context and Analyst Perspectives

This event highlights the critical importance of robust corporate governance and transparency, particularly within the healthcare sector. Ethical missteps and financial reporting irregularities can rapidly erode investor confidence and significantly impact stock valuations, especially in an environment of increasing regulatory scrutiny.

Analyst reactions have been varied, reflecting the heightened uncertainty. JPMorgan downgraded PACS Group to neutral from overweight, adjusting its price target to $18 from $40. Meanwhile, Truist Securities cut its price target to $32 from $46, while maintaining a buy rating.

Despite these significant challenges, PACS Group has continued its expansion strategy in the post-acute healthcare sector. As of June 30, 2025, the company had added 96 facilities since the second quarter of 2024, bringing its total portfolio to 316 healthcare facilities across 17 states. Preliminary operational metrics for the first six months of 2025 indicate strong performance, with total facilities occupancy at 88.9%, significantly higher than the industry average of 78.0%. Furthermore, the company reported $294.2 million in cash and cash equivalents as of June 30, 2025, an increase from $157.7 million at the end of 2024.

Looking Ahead

CEO Jason Murray expressed confidence, stating that once the company becomes current with its SEC filings, he expects to report record revenue and adjusted EBITDA for the first half of 2025 and plans to "accelerate growth" following the completion of the Audit Committee's investigation. The stock currently holds a P/E ratio of 21.47, with analyst targets ranging from $18 to $40, suggesting potential for upside according to InvestingPro data.

Investors will closely monitor the company's progress in addressing its delisting threat and regaining compliance with SEC and NYSE standards. The outcome of the ongoing internal probe and the restatement of past financial results will be crucial in restoring investor confidence and determining the future trajectory of PACS Group's stock. The significant divergence in analyst price targets underscores the high level of uncertainty surrounding the company's near-term prospects.